Further studies are warranted to experimentally validate the predicted CA5A inhibitory activities of RA and CGA and to investigate the hypolipidemic and antioxidant activities of the proposed plant extracts in animal models of dyslipidemia and obesity. This evidence concerns the gene CA5A and obesity due to melanocortin 4 receptor deficiency.